Regent Pacific completes acquisition of Deep Longevity

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

The Hong Kong group has acquired the Longevity AI and aging clock specialist Deep Longevity.

In a move that cements their expansion into the emerging field of AI and Longevity medicine (while strengthening the shareholder mix by adding experienced Longevity and wellness biotechnology investors and entrepreneurs) Regent Pacific has successfully completed its previously-announced acquisition of Deep Longevity.

Longevity.Technology: Longevity conjures up ideas of lifespans and decades, but Deep Longevity has successfully demonstrated that speed is important too. Insilico Medicine announced that its spin-out Deep Longevity had exited stealth just five months ago, and it came out of the gate strong, having secured a collaboration with Human Longevity Inc to deploy an extensive range of AI-powered aging clocks.

Originally backed by venture capitalists specialising in biotechnology, Longevity and AI, including ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC and the co-founder of Oculus, Michael Antonov, Deep Longevity’s pace hasn’t let up, either, with news of its biometric-crunching Young.AI app, a collaboration with Longenesis and a new Longevity Medicine for Physicians course following hot on the heels of its acquisition by Regent Pacific. It is exciting to see the speed and breadth of their accomplishments and Deep Longevity makes a worthy jewel in the Regent’s crown.

Pursuant to the Share Purchase Agreements, Regent Pacific has acquired all the issued and outstanding securities in Deep Longevity Inc, at the total consideration of US$3.79 million, which was satisfied by the issue and allotment by the Company of an aggregate of 422.69 million consideration shares.

Regent Pacific is a Hong Kong-based diversified investment group based in Hong Kong, specialising in healthcare, wellness and life sciences investments. The group has returned approximately US$298 million to shareholders in the 23 years of financial reporting since its initial public offering in May 1997.

Jamie Gibson, Chief Executive Officer of Regent Pacific, said, “We are delighted to have completed the acquisition of Deep Longevity as it signifies a major milestone in our development in becoming a global end-to-end longevity and wellness biotechnology company.

 


 

“Deep Longevity … aspires to be a leader in the field of machine learning for personalised preventative healthcare and longevity interventions.”

 


 

“Deep Longevity provides users with the most efficient, reliable and useful aging and longevity clocks that can help people live better, longer and healthier lives, with its patented DNA deep methylation clock being the most accurate in its field. Deep Longevity possesses first-mover advantage in Asia, has state-of-the-art technology driven by AI and aspires to be a leader in the field of machine learning for personalised preventative healthcare and longevity interventions.

“The acquisition will allow Regent Pacific to expand into the global wellness market that was estimated to be over US$4.20 trillion in 2017. Deep Longevity’s sophisticated AI system is uniquely able to track the rate of human aging and evaluate the effectiveness of longevity interventions.”

Alex Zhavoronkov, PhD, founder and CEO of Deep Longevity, said: “We are pleased to reach this important milestone for Deep Longevity. As part of Regent Pacific, we are excited to add our scientists and experts to the Group which aim to serve the longevity biotechnology industry as well as the health and life insurance industries and become the ultimate instrument to hedge the longevity risk.”

Image credit: By Kapi Ng / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

A brain fitbit that can spot Alzheimer’s with up to 94% accuracy

Altoida raising new financing for augmented reality cognitive assessment platform that dramatically improves early detection of Alzheimer’s and other neurodegenerative diseases. Earlier this year, AR-powered...

Apollo closes $180m for age-related disease innovations

Apollo Health Ventures fund will drive breakthrough innovations combating age-related diseases. Apollo Health Ventures has announced the final closing of its second venture fund to...

Insilico starts human trial with AI-discovered drug

First human dosed with AI-discovered novel molecule based on an AI-discovered novel target. Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, has announced that the...

    Subscribe to our newsletter